Since high levels of CD24 were associated with worse survival in both MCL and CLL, anti‐CD24‐induced phagocytosis could be considered for future clinical use, particularly in association with other agents such as Rituximab. The gene discussed is CD24; the disease is B-cell chronic lymphocytic leukemia.